Novo misses in Alzheimer's trial; Insurer shares rise on report Trump will unveil health policy proposal; Bayer’s stroke drug succeeds in late-stage trial.

Novo Nordisk is chopping prices again for Wegovy, but doctors say the expense will remain challenging for patients without ...

U.S. stock futures were flat and international equities mixed amid further signs of returning calm after last week’s ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

Septerna's Novo partnership brings $195M upfront, a potential $2.2B in milestones, and full R&D funding. Read why SEPN stock ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

The U.S. stock market rallied. The S&P 500 climbed 1.5% Monday for one of its best days since the summer and added to its ...

Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

Broadcom’s stock surged 11.10% to close at $377.96, reaching an intraday high of $382 and a low of $347.66. The stock’s ...

Jared Holz, Mizuho, joins 'Fast Money' to talk Novo Nordisk shares sliding on latest drug trial and how to treat the stock at ...

A pill version of A/S’s Ozempic failed to slow the progression of Alzheimer’s disease in a pair of long-shot studies that ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...